Table 3.
Overall survival (OS) for 48 patients enrolled on study
| Variable | N | Median (mo) | 1-year OS | 2-year OS | 5-year OS | HR | 95% CI | P |
|---|---|---|---|---|---|---|---|---|
| All subjects | 48 | 24.39 (18.87, 29.65) | 93 (86, 100) | 51 (37, 71) | 20 (10, 42) | |||
| Age <65 | 32 | 24.69 (19, 37.38) | 94 (85, 100) | 57 (40, 81) | 19 (8, 49) | 1 | - | |
| Age 65+ | 16 | 21.11 (18.28, 72.8+) | 93 (82, 100) | 42 (22, 82) | 25 (10, 67) | 0.91 | (0.41, 2.01) | .81 |
| Tumor diameter ≤3 cm | 23 | 31.46 (28.18, 72.8+) | 96 (88, 100) | 78 (60, 100) | 34 (15, 78) | 1 | - | |
| Tumor diameter >3 cm | 25 | 18.87 (18.21, 25.08) | 91 (81, 100) | 31 (16, 60) | 10 (3, 38) | 2.69 | (1.22, 5.96) | .01 |
| Isolated recurrence pattern | 40 | 26.73 (18.38, 72.8+) | 92 (84, 100) | 60 (45, 81) | 29 (16, 55) | 1 | - | |
| Synchronous recurrence pattern | 8 | 19.13 (18.87, 72.8+) | 100 (100, 100) | 25 (8, 83) | 0 (NA, NA) | 1.90 | (0.82, 4.39) | .13 |
| Negative margin status | 20 | 19 (18.21, 72.8+) | 100 (100, 100) | 39 (21, 72) | 10 (2, 53) | 1 | - | |
| Positive margin status | 28 | 25.08 (19.27, 72.8+) | 89 (77, 100) | 62 (44, 88) | 31 (15, 63) | 0.65 | (0.31, 1.38) | .26 |
| Male | 7 | 29.65 (24.69, 72.8+) | 100 (100, 100) | 83 (58, 100) | 28 (5, 100) | 1 | - | |
| Female | 41 | 21.11 (18.38, 31.46) | 92 (84, 100) | 46 (31, 68) | 18 (8, 43) | 1.26 | (0.44, 3.66) | .67 |
| Uninvolved lymph nodes | 32 | 25.08 (19, 72.8+) | 97 (90, 100) | 54 (36, 81) | 15 (3, 61) | 1 | - | |
| Involved lymph nodes | 16 | 19.27 (18.28, 72.8+) | 88 (73, 100) | 48 (28, 81) | 20 (7, 56) | 1.09 | (0.51, 2.33) | .82 |
| Grade <3 | 10 | 21.34 (18.87, 72.8+) | 89 (71, 100) | 38 (16, 92) | 25 (8, 84) | 1 | - | |
| Grade 3+ | 38 | 24.69 (18.38, 37.38) | 95 (88, 100) | 56 (40, 78) | 19 (8, 46) | 0.88 | (0.37, 2.07) | .76 |
| Tumor in body/tail | 34 | 21.34 (19, 29.06) | 97 (91, 100) | 48 (31, 74) | 16 (6, 44) | 1 | - | |
| Tumor in head | 14 | 24.69 (16.21, 72.8+) | 85 (67, 100) | 54 (33, 89) | 26 (9, 74) | 0.79 | (0.35, 1.78) | .57 |
| ECOG 0 | 23 | 19 (16.57, 29.65) | 90 (79, 100) | 38 (19, 73) | 8 (1, 49) | 1 | - | |
| ECOG 1 | 23 | 28.18 (21.34, 72.8+) | 96 (88, 100) | 68 (50, 93) | 32 (14, 71) | 0.37 | (0.17, 0.83) | .02 |
| Baseline CA19-9 above median | 14 | 18.28 (16.57, 72.8+) | 85 (67, 100) | 42 (20, 88) | 11 (2, 67) | 1 | - | |
| Baseline CA19-9 below median | 34 | 24.69 (19.27, 72.8+) | 97 (91, 100) | 55 (38, 78) | 24 (10, 54) | 0.53 | (0.24, 1.16) | .11 |
Abbreviations CI = confidence interval; ECOG = Eastern Cooperative Oncology Group; HR = hazard ratio.
Median survival is shown in months with a 95% CI. Values for OS probability at 1, 2, and 5 years are shown with 95% CIs. All HRs and P values are from univariate models.